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Abstract
Introduction: Aneurysmal subarachnoid hemorrhage (SAH) affects relatively young people and carries a poor
prognosis with a case fatality rate of 35%. One of the major systemic complications associated with SAH is acute
lung injury (ALI) which occurs in up to one-third of the patients and is associated with poor outcome. ALI in SAH
may be predisposed by neurogenic pulmonary edema (NPE) and inflammatory mediators. The objective of this
study was to assess the immunomodulatory effects of interferon-b (IFN-b) on inflammatory mediators in the lung
after experimental SAH.
Methods: Male Wistar rats were subjected to the induction of SAH by means of the endovascular filament
method. Sham-animals underwent sham-surgery. Rats received IFN-b for four consecutive days starting at two
hours after SAH induction. After seven days, lungs were analyzed for the expression of inflammatory markers.
Results: SAH induced the influx of neutrophils into the lung, and enhanced expression of the pulmonary adhesion
molecules E-selectin, inter-cellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1
compared to sham-animals. In addition, SAH increased the expression of the chemokines macrophage
inflammatory protein (MIP)-1a, MIP-2, and cytokine-induced neutrophil chemoattractant (CINC)-1 in the lung.
Finally, tumor necrosis factor-a (TNF-a) was significantly increased in lungs from SAH-animals compared to sham-
animals. IFN-b effectively abolished the SAH-induced expression of all pro-inflammatory mediators in the lung.
Conclusions: IFN-b strongly reduces lung inflammation after experimental SAH and may therefore be an effective
drug to prevent SAH-mediated lung injury.
Introduction
Aneurysmal subarachnoid hemorrhage (SAH) affects
patients at a relatively young age and has an incidence
of 5 to 7 per 100,000 person-years. SAH carries a bad
prognosis with a case fatality rate of 35% [1]. Systemic
complications including cardiac failure, pneumonia, and
pulmonary edema, occur in more than half the patients
with SAH, and are an important contributor to poor
outcome [2].
Acute lung injury (ALI) is commonly associated with
brain injury and has an incidence between 5 and 30% in
SAH patients [2-5]. The development of ALI after SAH
is an independent predictor of increased mortality and
poor neurological outcome in patients suffering from
SAH. One of the major components of ALI is the
formation of pulmonary edema. Neurogenic pulmonary
edema (NPE) is a life-threatening complication in
patients suffering from SAH and is associated with a
three-fold increase in poor outcome [6].
T h ep r o p o s e de t i o l o g yo fN P Ei sam a s s i v es y m p a -
thetic discharge following severe brain injury leading to
intra-alveolar accumulation of protein-rich edema fluid
and hemorrhage. The pathogenesis of NPE is still
incompletely understood. A well-established theory on
the pathophysiology of NPE is the blast-theory,w h i c h
proposes combined hydrostatic and high permeability
mechanisms for the formation of NPE due to the sym-
pathetic storm caused by an acute increase in intracra-
nial pressure [7]. Recently, it has been suggested that a
systemic inflammatory response may also play a pivotal
role in the development of pulmonary dysfunction after
traumatic brain injury [8,9]. The effects, however, of
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including the lung are still unknown.
Current therapy is mainly supportive since no effective
drugs are available to treat NPE. Mechanical ventilation
(MV) is necessary in the majority of patients to assure
adequate oxygenation. However, MV can also contribute
to lung injury, called ventilation-induced lung injury
(VILI) [10]. A staggering 40% of SAH patients on MV
develop VILI [11].
Interferon-b (IFN-b) is a small protein with immuno-
modulatory properties that has been approved for treat-
ment of multiple sclerosis. It has been shown that IFN-b
decreases pro-inflammatory cytokines and inhibits the
migration of lymphocytes across the blood-brain barrier
by decreasing the expression of chemokines and adhesion
molecules on endothelial cells [12].
T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t e
whether experimental SAH contributes to lung inflam-
mation. Moreover, we examined the effects of IFN-b
treatment on the expression of inflammatory mediators
in the lung associated with brain injury in a rat model
of SAH.
Materials and methods
Animals
The experiments were performed in accordance with
international guidelines and approved by the experimen-
tal animal committee of the Academic Biomedical Cen-
ter Utrecht. Male Wistar rats (weighing 320 to 350 g)
were obtained from Harlan CPB (Horst, The Nether-
lands) and randomly assigned to the different treatment
groups. Both the executers of the experiments and of
the statistical analysis were blind for randomization.
Experimental SAH-model
Rats were intubated under gaseous anesthesia (65% air/
33% oxygen/2% isoflurane) and mechanically ventilated
for a maximal 90 minutes in a pressure controlled time-
cycled mode, at a fractional inspired oxygen concentra-
tion (FiO2) of 0.5, inspiration to expiration (I/E) ratio of
1:1 and peak inspiratory pressure of 10 cmH2O. To
maintain normocapnia, the respiratory rate was set at
55 breaths per minute. The left external carotid artery
(ECA) was ligated and cut, while the ipsilateral internal
carotid artery (ICA) and communal carotid artery were
temporarily clipped. A sharpened 4.0 prolene suture was
introduced through an opening in the ligated left ECA
and distally advanced through the ICA until the suture
perforated the intracranial bifurcation of the ICA. In
sham-animals, the suture was withdrawn prior to perfor-
ating the ICA. The presence of subarachnoidal blood
was confirmed with magnetic resonance imaging.
Animals were treated for four consecutive days with
subcutaneous injections of 1.75 × 10
6 U/kg IFN-b
(U-Cytech, Utrecht, The Netherlands) (SAH-animals:
N =6 ;s h a m - a n i m a l s :N = 4) or saline (SAH-animals:
N = 7; sham-animals: N = 4) starting at two hours after
SAH. Treatment dosage and time of treatment were
based on previous results of Veldhuis et al. where IFN-b
proved to be clinically efficacious by reducing the influx
of inflammatory cells into the brain and reducing infarct
volume in a rat model of ischemic stroke when started
up to six hours after the induction of stroke [13]. Since
we wanted to initiate treatment as soon as possible, but
with respect to a realistic clinical moment at which
patients are admitted to a hospital, we decided to start
treatment at two hours after the induction of stroke.
Preparation of tissue homogenates
Lungs were removed at seven days post-SAH. Tissues
were pulverized using a liquid nitrogen-cooled mortar
and pestle and stored at -80°C for further analysis.
Myeloperoxidase (MPO) assay
MPO activity was determined as described previously
[14]. Briefly, pulverized tissues were homogenized in
50 mM HEPES buffer (pH 8.0), centrifuged and pellets
were rehomogenized in H2O/0.5% cetyltrimethylammo-
nium chloride (CTAC; Merck, Darmstadt, Germany).
After centrifugation, supernatants were diluted in
10 mM citrate buffer (pH 5.0)/0.22% CTAC. Substrate
solution containing 3 mM 3’,5,5’-tetramethylbenzidine
dihydrocloride (TMB; Sigma-Aldrich, Steinheim, Ger-
many), 120 μM resorcinol (Merck) and 2.2 mM H2O2 in
distilled water was added. Reaction mixtures were incu-
bated for 20 minutes at room temperature and stopped
by 4 M H2SO4, followed by determination of optical
density at 450 nm. MPO activity of a known amount of
MPO units (Sigma-Aldrich) was used as reference.
Quantitative real-time reverse transcriptase (RT)-PCR
analysis
Total RNA was isolated from pulverized tissues with
TRIzol® reagent (Invitrogen, Paisley, UK). cDNA was
synthesized from total RNA with SuperScript Reverse
Transcriptase kit (Invitrogen). Quantitative real-time
RT-PCR reaction was performed with iQ5 Real-Time
PCR Detection System (Biorad, Hercules, CA, USA)
using rat primers for TNF-a, macrophage inflammatory
protein (MIP)-1a,M I P - 2 ,c y t o k i n e - i n d u c e dn e u t r o p h i l
chemoattractant (CINC)-1, E-selectin, inter-cellular
adhesion molecule (ICAM)-1, and vascular cell adhesion
molecule (VCAM)-1. Data were normalized for expres-
sion of internal controls, b-actin and GAPDH.
Statistical analysis
Data are expressed as mean ± standard error of mean
(SEM). All parameters were evaluated by one-way
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Difference (LSD) post-test. P-values < 0.05 were consid-
ered statistically significant.
Results
Stability of the model
SAH was induced at Day 0 in male Wistar rats and treated
for four consecutive days with IFN-b. At Day 7, placebo-
treated rats showed a case fatality rate of 50%, whereas
IFN-b-treated animals showed a case fatality rate of 63%,
although this difference was not statistically significant. All
animals that did not survive the protocol died within the
first three days after the induction of SAH.
IFN-b inhibits the influx of neutrophils into the lung
As a parameter for the number of infiltrating neutro-
phils we determined myeloperoxidase (MPO)-activity in
total lung homogenates at Day 7 post-SAH. SAH-ani-
mals had a significant increase in MPO-activity com-
pared to sham-animals (P < 0.01), which could be
efficiently blocked by IFN-b (P < 0.01; Figure 1a).
IFN-b inhibits the expression of endothelial activation
markers and pulmonary chemokines
Because neutrophil influx is dependent on the activation
of endothelial cells, we studied the effect of SAH on
endothelial adhesion molecules in lung tissue. Compared
to sham-animals, SAH increased pulmonary expression
of E-selectin (P < 0.01), inter-cellular adhesion molecule
(ICAM)-1 (P < 0.001), and vascular cell adhesion mole-
cule (VCAM)-1 (P < 0.01). IFN-b normalized the
expression of E-selectin (P < 0.01), ICAM-1 (P < 0.01)
and VCAM-1 (P < 0.01) compared to saline-treated
SAH-rats (Figure 1b-d).
To establish whether the attraction of neutrophils is
correlated with the expression of chemokines, we next
questioned whether SAH induced the expression of pul-
monary macrophage inflammatory protein (MIP)-1a,
MIP-2, and cytokine-induced neutrophil chemoattrac-
tant (CINC)-1. All chemokines were significantly
increased in lungs from SAH-rats (P < 0.05). Treatment
with IFN-b completely abolished the SAH-induced
upregulation of the chemokines MIP-1a (P <0 . 0 1 ) ,
MIP-2 (P < 0.01), and CINC-1 (P < 0.05) (Figure 1e-g).
IFN-b reduces pulmonary TNF-a expression
To determine whether SAH induced pro-inflammatory
cytokine expression in the lung, we measured TNF-a
expression. SAH resulted in a significant three-fold
increase in pulmonary TNF-a expression compared to
sham-animals (P <0 . 0 1 ) .I F N - b treatment significantly
decreased the SAH-induced TNF-a expression to the
levels observed in IFN-b treated sham-animals
(P < 0.05; Figure 1h).
Discussion
We report here that SAH induces the influx of neutro-
phils into the lung and expression of pulmonary adhesion
molecules, chemokines, and TNF-a. More importantly,
we are the first to show that IFN-b effectively abolishes
the SAH-induced expression of all pro-inflammatory
mediators in the lung.
SAH rats showed a case fatality rate of 50% after seven
days. The mortality observed by us is common in
experimental SAH-models and resembles other findings
[15-17]. Treatment with IFN-b resulted in a case fatality
rate of 63%, although this increase did not statistically
differ from the placebo group.
Neutrophils play an essential role in the development
of lung inflammation. We observed a four-fold increase
in MPO, indicating that neutrophils are recruited to the
lung following SAH. The influx of neutrophils involves a
complex cascade of events. The early response cytokine,
TNF-b, most probably initiates the inflammatory
response by activating the endothelial cells resulting in
increased chemokine expression and upregulation of
adhesion molecules [18]. In support of this concept we
showed increased expression of pulmonary TNF-a
following SAH. In addition, SAH induced enhanced pul-
monary expression of the endothelial adhesion mole-
cules E-selectin, ICAM-1, and VCAM-1, which play a
pivotal role in the rolling across the endothelium and
firm adhesion of neutrophils to the endothelium, respec-
tively [18]. Furthermore, we observed marked SAH-
induced upregulation of the chemokines MIP-1a,
MIP-2, and CINC-1, which are responsible for the che-
motactic activity of neutrophils. Therefore, we conclude
that SAH induces a pro-inflammatory environment in
the lung which may represent an important risk factor
for the development of NPE.
Although several groups reported the occurrence of
lung injury after brain injury, the underlying mechan-
isms are largely unknown. It has been suggested that
increased intracranial production of pro-inflammatory
cytokines results in the release of systemic pro-inflam-
matory mediators, thereby promoting secondary organ
injury [8]. Although this is a tempting hypothesis, we
show here de novo synthesis of pro-inflammatory media-
tors, suggesting that spill-over of cytokines is not the
primary cause of lung inflammation following SAH. A
second proposed mechanism underlying secondary
organ injury is increased capillary permeability elicited
by catecholamines due to sympathetic nerve stimulation
after brain injury [7]. Catecholamines can activate the
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Page 3 of 6Figure 1 SAH was induced in male Wistar rats.R a t sw e r et r e a t e dw i t hI F N - b for four consecutive days starting at two hours after the
induction of SAH. Seven days post-SAH total lung homogenates were prepared and analyzed for inflammatory markers. (a) MPO activity
corrected for the amount of protein. (b-d) Expression of endothelial activation markers E-selectin, ICAM-1, and VCAM-1. (e-g) Expression of
chemokines MIP-1a, MIP-2, and CINC-1. (h) Expression of TNF-a. (b-h) Data are normalized for the expression of b-actin and GAPDH. Sham:
N = 4; Sham/IFN-b: N = 4; SAH: N = 7; SAH/IFN-b: N = 6. *** P < 0.001, ** P < 0.01, * P < 0.05; SAH vs sham or SAH/IFN-b vs SAH. MPO,
myeloperoxidase; MIP, macrophage-inflammatory protein; CINC, cytokine-induced neutrophil chemoattractant.
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moting the production of TNF-a chemokines, and adhe-
sion molecules [19,20]. Therefore, we propose that
sympathetic activation of the lung could have led to the
local release of cytokines and chemokines in our model.
The major finding of our study was that IFN-b treat-
ment strongly attenuates the SAH mediated pulmonary
inflammation. The decreased influx of neutrophils in
response to IFN-b administration was accompanied by
decreased expression of TNF-a, chemokines, and adhe-
sion molecules in the lung. Although this is an interest-
ing finding, one should keep in mind that IFN-b therapy
may also worsen bacterial pneumonia [21], although
until now only one case-report has been published.
However, the increase in incidence of bacterial pneumo-
nia was only described for a situation in which long-
term treatment with IFN-b was applied [22]. IFN-b is a
potent immunomodulator with diverse effects. Several
studies have shown that IFN-b reduces the migration of
inflammatory cells across the blood-brain barrier [12].
This is likely accomplished by reducing the expression
of endothelial adhesion molecules, ICAM-1 and VCAM-
1, and by downregulating the production of chemokines
[23,24]. Although the immunomodulatory effects of
IFN-b have been described in brain-related diseases
including multiple sclerosis and focal cerebral ischemia,
we are the first to describe the modulatory effects of
IFN-b in pulmonary inflammation. The exact mechan-
isms by which IFN-b attenuates SAH-induced lung
inflammation need to be further clarified. In our study,
IFN-b was administered systemically; therefore it may
be possible that IFN-b had a direct effect on pulmonary
cells. For example, Kiss et al. showed that IFN-b treat-
ment ameliorated vascular leakage in ALI via upregula-
tion of 5’-nucleotidase (CD73) on pulmonary endothelial
cells [25]. Although we did not look at CD73, it could
be a possible explanation for our findings. IFN-b could
also have an indirect effect by inhibiting either the acti-
vation of sympathetic nervous system or reducing the
systemic pro-inflammatory environment and subse-
quently preventing the upregulation of pro-inflammatory
mediators in the lung. Although we did not measure
catecholamines, we could not see an effect of IFN-b
treatment on TNF-a levels in the blood (data not
shown). Finally, IFN-b could have a direct effect on cer-
ebral inflammatory responses after SAH, thereby indir-
ectly regulating the lung inflammation. Our preliminary
data do not confirm this hypothesis since IFN-b did not
have any effect on the SAH-induced cerebral inflamma-
tion (manuscript in preparation, Tiebosch et al.)
In conclusion, SAH induces a pro-inflammatory envir-
onment in the lung, which can be efficiently blocked by
IFN-b. Therefore, our data strongly suggest that IFN-b
may be an attractive clinical candidate to prevent SAH
mediated lung inflammation.
Conclusions
We show here that subarachnoid hemorrhage (SAH)
results in the upregulation of pro-inflammatory media-
tors in the lung as well as recruitment of neutrophils
into the lung. In addition, we report that treatment with
IFN-b completely abolishes the SAH-induced pulmonary
inflammation. Our data imply that SAH is associated
with pulmonary inflammation and that IFN-b may be
an attractive therapeutic candidate to prevent SAH-
mediated lung inflammation.
Key messages
￿ Subarachnoid hemorrhage in rats is associated with
increased pulmonary inflammatory mediators.
￿ Subarachnoid hemorrhage results in increased
neutrophil influx into the lung.
￿ IFN-b treatment completely abolishes the subarach-
noid hemorrhage-induced pulmonary inflammation.
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